EVALUATION OF HEMATOLOGICAL BLOOD PARAMETERS IN PATIENTS FOLLOWING SURGICAL TUMOR REMOVAL AND CHEMOTHERAPY DURING REHABILITATION WITH A THERAPEUTIC AND PROPHYLACTIC COMPLEX

Authors:

Abstract:

The study evaluated the effect of a therapeutic and preventive complex on haematological parameters following surgery for head and neck cancer and chemotherapy. Thirty-five adults aged 25–55 years were examined: 10 healthy controls, 10 comparison-group patients and 15 main-group patients. Haemoglobin concentration and erythrocyte and leukocyte counts were assessed at baseline and after 1, 3, 6 and 12 months. Baseline values were below control values (p<0.001). At 12 months, haemoglobin, erythrocyte and leukocyte values in the main group were 140.3±8.3 g/L, 4.8±0.4×1012/L and 5.1±0.3×109/L, representing increases of 99.9 %, 84.6 % and 70.0 %, respectively. Recovery was numerically greater with the complex.

Keywords:

head and neck cancer chemotherapy maxillofacial surgery haemoglobin erythrocytes leukocytes therapeutic and preventive complex

References:

1. Zhero NI, Zhero SV, Jenča A, Jenča A, Petrášová A. Osoblyvosti patolohii tverdykh tkanyn zubiv u onkolohichnykh khvorykh pid vplyvom khimioterapii. Naukovyi visnyk Uzhhorodskoho universytetu. Seriia Medytsyna. 2023;2(68):228-234. DOI:10.32782/2415-8127.2023.68.38. [in Ukrainian].
2. Rohach IM, Keretsman AO, Sitkar AD. Pravylno vybranyy metod statystychnoho analizu – shlyakh do yakisnoyi interpretatsiyi danykh medychnykh doslidzhen. Naukovyy visnyk Uzhhorodskoho universytetu, seriya "Medytsyna". 2017;2(56):124–128. [in Ukrainian].
3. Belfiore E, Di Prima G, Angellotti G, Panzarella V, De Caro V. Plant-derived polyphenols to prevent and treat oral mucositis induced by chemo- and radiotherapy in head and neck cancers management. Cancers (Basel). 2024;16(2):260. DOI:10.3390/cancers16020260.
4. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197-1210. DOI:10.1182/bloodadvances.2018030387.
5. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423-4431. DOI:10.1002/cncr.33100.
6. Ferraboschi P, Ciceri S, Grisenti P. Applications of lysozyme, an innate immune defense factor, as an alternative antibiotic. Antibiotics (Basel). 2021;10(12):1534. DOI:10.3390/antibiotics10121534.
7. Goyal N, Day A, Epstein J, Goodman J, Graboyes E, Jalisi S, et al. Head and neck cancer survivorship consensus statement from the American Head and Neck Society. Laryngoscope Investig Otolaryngol. 2022;7(1):70-92. DOI:10.1002/lio2.702.
8. Hong BY, Sobue T, Choquette L, Dupuy AK, Thompson A, Burleson JA, et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome. 2019;7(1):66. DOI:10.1186/s40168-019-0679-5.
9. Jiang C, Wang H, Xia C, Dong Q, Chen E, Qiu Y, et al. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer. 2019;125(7):1081-1090. DOI:10.1002/cncr.31907.
10. Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021;40(5):2898-2913. DOI:10.1016/j.clnu.2021.02.005.
11. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50. DOI:10.1182/blood-2018-06-856500.
12. Wondimneh B, Anekere Dasappa Setty S, Gebregzabher Asfeha G, Belay E, Gebremeskel G, Baye G. Comparison of hematological and biochemical profile changes in pre- and post-chemotherapy treatment of cancer patients attended at Ayder Comprehensive Specialized Hospital, Mekelle, Northern Ethiopia 2019: a retrospective cohort study. Cancer Manag Res. 2021;13:625-632. DOI:10.2147/CMAR.S274821.
13. Wu Q, Zhu C, Zhang S, Zhou Y, Zhong Y. Hematological toxicities of concurrent chemoradiotherapies in head and neck cancers: comparison among cisplatin, nedaplatin, lobaplatin, and nimotuzumab. Front Oncol. 2021;11:762366. DOI:10.3389/fonc.2021.762366.
14. Xia C, Jiang C, Li W, Wei J, Hong H, Li J, et al. A phase II randomized clinical trial and mechanistic studies using improved probiotics to prevent oral mucositis induced by concurrent radiotherapy and chemotherapy in nasopharyngeal carcinoma. Front Immunol. 2021;12:618150. DOI:10.3389/fimmu.2021.618150.
15. Yarom N, Hovan A, Bossi P, Ariyawardana A, Jensen SB, Gobbo M, et al. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines-part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. Support Care Cancer. 2020;28(5):2457–2472. DOI:10.1007/s00520-019-05256-4.

Publication:

«World of Medicine and Biology» Vol. 22 No. 97 (2026), pp. 32-38
UDC [616-053.88+616-006.04]:616.31-08-039.71

DOI:

https://doi.org/10.26724/2079-8334-2026-3-97-32-38